Back to Search
ROBERT ILARIA, M.D.
M.D.
Medical Oncology Physician
NPI: 1720177934Individual
Specialties, Licenses & Credentials
Research & Publications (20)
Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells.
PMID 18949427·Oncol Rep·2008
8-other
Hypoxia-induced modifications in plasma membranes and lipid microdomains in A549 cells and primary human alveolar cells.
PMID 18636548·J Cell Biochem·2008
8-other
Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo.
PMID 17277106·J Immunol·2007
7-preclinical
STAT5 signaling is required for the efficient induction and maintenance of CML in mice.
PMID 16522816·Blood·2006
4-observational
Pathobiology of lymphoid and myeloid blast crisis and management issues.
PMID 16304379·Hematology Am Soc Hematol Educ Program·2005
8-other
Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors.
PMID 16204038·Cancer Res·2005
7-preclinical
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
PMID 15657179·Blood·2005
7-preclinical
Animal models of chronic myelogenous leukemia.
PMID 15271391·Hematol Oncol Clin North Am·2004
6-review
Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
PMID 15161712·Clin Cancer Res·2004
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 462 1ST AVE
NEW YORK, NY 10016 - Phone
- (212) 562-5555
Quick Facts
- NPI
- 1720177934
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile